FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

Zimmer Biomet Holdings launched a new educational campaign targeting people living with joint pain. 1 The campaign is ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Results from a Phase III study in pediatric patients demonstrated that Odactra reduced the total combined rhinitis score by 22% compared to placebo.

Take degenerative disc disease, for example. When you take a fibroblast cell and you put it into the nucleus of the disc, you ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...